1 recruiting, 1 terminated, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow Theodore Laetsch: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors PEEL-224, Vincristine, Temozolomide (TMZ) - Refractory Solid Tumors, Relapsed Solid Tumors | Phase 1 / Phase 2 | Recruiting | Theodore Laetsch | 59 | 2025-03-23 | 2026-10-06 |
| HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors Doxorubicin HCl liposomal injection, Philips Sonalleve MR-HIFU Hyperthermia - Rhabdomyosarcoma, Neuroblastoma | Phase 1 | Withdrawn | Theodore Laetsch | 2016-12-01 | 2019-03-19 | |
| A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors Erlotinib, Sirolimus - Relapsed / Recurrent Germ Cell Tumors | Phase 2 | Terminated | Theodore Laetsch | 4 | 2014-01-08 | 2019-02-26 |
Neuroblastoma (2) · Rhabdomyosarcoma (2) · Desmoid Tumors (1) · Neoplasms, Germ Cell and Embryonal (1) · Osteosarcoma (1) · Recurrence (1) · Sarcoma (1) · Sarcoma, Ewing (1)
Erlotinib Hydrochloride (1) · Sirolimus (1) · Temozolomide (1) · Vincristine (1) · liposomal doxorubicin (1)
United States (3)